Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Bristol-Myers And Vanderbilt Team Up
by Lisa M. Jarvis
October 1, 2012
| A version of this story appeared in
Volume 90, Issue 40
Bristol-Myers Squibb has teamed with the Vanderbilt Center for Neuroscience Drug Discovery to develop new drugs for the treatment of Parkinson’s disease. The Vanderbilt center, supported by funding from the Michael J. Fox Foundation, has discovered positive allosteric modulators of the mGluR4 glutamate receptor. Drug candidates will be identified from that program, and BMS will have the right to further develop them. As part of the pact, Vanderbilt University will receive an undisclosed up-front fee and several years of research funding for the discovery of other compounds.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X